

TOP 4.1



RTD

H2020-PHC-2014-Single stage

**54 eligible proposals
evaluated by 57 experts**



H2020-PHC-7-2014-Single stage

**10 eligible proposals
evaluated by 7 experts**

PHC-7

Outcome of evaluation:

- **Indicative budget: € 20.0 million**
- **Allocated budget: € 20.81771 million**
- **Coverage of the topic: yes**

<i>Received</i>	<i>passed</i>	<i>Short-listed (success rate)</i>	<i>reserve</i>
10	3 (30%)	1 (10%)	1

General remarks

- **Very high interest for PHC-7**
- **30 % above threshold and covering well the topic - 20 % are of high quality**
- **8 SMEs involved, 2 in the selected proposal**

COMPARE aims to improve the identification and mitigation of emerging infectious diseases and foodborne outbreaks by establishing a “One serves all” analytical framework and data exchange platform that will allow real time analysis and interpretation of sequence-based pathogen data in combination with associated data (e.g. clinical, epidemiological data) in an integrated inter-sectorial, interdisciplinary, international, “one health” approach.



H2020-PHC-8-2014-Single stage

**30 eligible proposals
requesting € 169.885.576 million
evaluated by 24 experts**

PHC-8

Outcome of evaluation:

- **Indicative budget: € 25.0 million**
- **Allocated budget: € 26.193667 million**
- **Coverage of the topic: yes**

<i>Received</i>	<i>passed</i>	<i>Short-listed (success rate)</i>	<i>reserve</i>
5	2 (40%)	2 (40%)	0

General remarks

- **Reasonable interest for PHC-8**
- **2/5 proposals of high quality, covering well the topic**
- **In the call 7 SMEs involved, 2 in the selected proposals**

Remarks on short-list

PHC-8

EMI-TB: The aim is to generate a novel vaccine candidate for tuberculosis that will either boost or supplement systemic BCG. Emphasis is on eliciting mucosal immunity.

TBVAC2020: The aim is to advance several novel and promising tuberculosis vaccine candidates from discovery to preclinical and early clinical development.



H2020-PHC-15-2014-Single stage

**5 eligible proposals
evaluated by 7 experts**

PHC-15

Clinical research on regenerative medicine

Outcome of evaluation:

- Indicative budget: € 36million
- Allocated budget : € 36 million
- Coverage of the topic: good

<i>Received</i>	<i>passed</i>	<i>Short-listed (success rate)</i>	<i>reserve</i>
30	7 (23%)	6 (20%)	1

General remarks

- Moderate number of proposals received
- Some applications of very high quality whereas many failed to present critically important preliminary data/regulatory advice for clinical trials
- The 6 ranked proposals include 7 SMEs (10.5 % of the budget of these proposals)
- Medical technology companies participate in 2 of the ranked proposals (TERUMO BCT, Cook Medical, Asklepios and Human Med Ag, Aries srl)

- 1. RETHRIM:** Restoring tissue regeneration in patients with visceral (acute) Graft versus Host Disease using allogeneic mesenchymal stromal cell transplantation
- 2. ARISE:** Decellularized allogeneic heart valve for aortic valve replacement in children/adolescent patients
- 3. TREGeneration:** Repair of tissue and organ damage in chronic Graft versus Host Disease after hematopoietic stem cell transplantation by infusion of purified allogeneic donor regulatory T lymphocytes

4. SCIENCE: Allogeneic adipose-derived stromal cell-based therapy to improve myocardial function in patients with ischemic heart disease and heart failure

5. SC0806: Regenerative treatment of complete Traumatic Spinal Cord Injury with a surgical implantation of a biodegradable device with FGF1 and nerve grafts

6. ADIPOA2: Clinical trial of autologous adipose-derived mesenchymal stromal cells in the treatment of mild to moderate osteoarthritis



H2020-PHC-31-2014-Single stage

**9 eligible proposals
evaluated by 6 experts**

PHC-31

Outcome of evaluation:

- **Indicative budget: € 6 million**
- **Allocated budget: € 5.649890 million (excl. reserve list)**
- **Coverage of the topic: yes**

<i>Received</i>	<i>passed</i>	<i>Short-listed (success rate)</i>	<i>reserve</i>
9	6 (67%)	2 (22%)	1 (11%)

General remarks

- **Reasonable interest for PHC-31**
- **33% over threshold, but no very high scores**
- **For the successful proposals**
 - **One SME**
 - **No industry involvement**

Euro-Healthy :

The project aims to advance knowledge as to which policies have the highest potential to enhance health and health equity across European regions and within metropolitan areas. Accounting for future scenarios and in two case studies (pilot metropolitan areas of Lisbon and Turin), this index will be the starting point to **foresee and discuss the impact of multilevel policies and how different combinations of policies can influence population health and geographical health inequalities**

Fresher:

The project aims to represent **alternative futures** where the detection of emerging health scenarios will be used to **test future policies to effectively tackle the burden of non-communicable diseases (NCDs)**. The project will produce quantitative estimates of the future global burden of NCDs in the EU and its impact on health care expenditures and delivery, population well-being, health and socio-economic inequalities, and potential changes in these impacts according to alternative health and non-health policy options